Therapeutics

Tvardi’s next-generation STAT3 inhibitor TTI-109 confirmed rapid prodrug conversion, dose-proportional exposure, and improved tolerability versus TTI-101 in Phase 1 testing. Investorideas.com (www.investorideas.com) a trusted platform for investing ideas, including biotech…

BriaCell Therapeutics (BCTX) priced a public offering of 5.37M units, with each unit consisting of one common share and one warrant. Each unit is being sold to the public at…

Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026…